The Daily Buyout
$945MStrategic acquisitionHealthcare & Life Sciences

GE HealthCare to buy SOFIE Biosciences for $945M from Trilantic

GE HealthCare agreed to acquire SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, from Trilantic North America for $945 million in cash. SOFIE operates 15 CMO sites and already manufactures GE HealthCare's Flyrcado F18 product; it will join the PDx pharmaceutical diagnostics segment on closing, expected in the first half of 2027. GE HealthCare also gains U.S. rights to pipeline tracer FAPI-74.

Why it matters: Radiopharmaceuticals live or die on last-mile logistics, and GE HealthCare is buying the distribution network to clear adoption bottlenecks.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

More Healthcare & Life Sciences deals

$5.8BTake-privateHealthcare & Life SciencesOct 7, 2026

CD&R and McKesson to take Option Care Health private for $5.8B

Clayton, Dubilier & Rice and McKesson agreed to acquire Option Care Health for $32.05 per share in a deal valued at about $5.8 billion. CD&R will hold majority ownership, while McKesson invests roughly $1.4 billion for about 49%, with a framework to potentially buy CD&R's stake later. Option Care shares jumped about 34%.

Read at SEC EDGARFree
$2BStrategic acquisitionHealthcare & Life SciencesOct 6, 2026

Shionogi pays $2B for rare disease biotech IntraBio

Japan's Shionogi agreed to acquire Texas-based IntraBio for $2 billion, adding the marketed drug Aqneursa for Niemann-Pick disease type C and Ataxia-Telangiectasia. IntraBio reported sales of $68 million in 2025. The purchase follows Shionogi's acquisitions of Radicava and Tetra Therapeutics as it builds out a rare neurodegenerative disease franchise.

Read at BioPharma DiveFree